ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study

Liu, Shousheng; Jiang, Chang; Yang, Lin; Huang, Jinsheng; Peng, Roujun; Wang, Xiaopai; He, Wenzhuo; Bai, Long; Zhou, Yixin; Zhang, Bei*; Xia, Liangping*广州医学院; 南方医科大学; 中山大学; 1
Scientific Reports2020-7-23DOI: 10.1038/s41598-020-69230-5
7被引7阅读
引用收藏
分享

摘要

The optimal targeted therapy sequence in patients of RAS wild-type left-sided metastatic colorectal cancer (mCRC) remains controversial, and few studies focus on the impact of first-line targeted agents on second-line ones. We enrolled 101 left-sided mCRC patients with RAS wild-type status, of which 50 cases received bevacizumab plus chemotherapy in both first-line and second-line therapies (Group A) and 51 cases received first-line cetuximab plus chemotherapy followed by second-line bevacizumab-containing regimens (Group B). The progression free survival (PFS) and overall survival (OS) from start of first-line (PFS 1nd and OS 1nd) and second-line (PFS 2nd and OS 2nd) therapy were compared between the two groups. PFS 1nd was comparable (10.0 vs 10.4 months; p=0.402), while PFS 2nd (4.6 vs 7.9 months; p=0.002), OS 1nd (26.8 vs 40.0 months; p=0.011), and OS 2nd (15.2 vs 22.3 months; p=0.006) were all poorer in group A compared with group B. Our study in combination with previous clinical data suggest that first-line application of cetuximab may provide a favorable condition for promoting the effect of subsequent bevacizumab, thus representing the optimal targeted therapy sequence in patients of RAS wild-type left-sided mCRC.

学科与关键词

关键词
FOLFIRI PLUS CETUXIMABPRIMARY TUMOR SITEACQUIRED-RESISTANCERANDOMIZED PHASE-32ND-LINE TREATMENTCOST-EFFECTIVENESSSALVAGE TREATMENTPROGNOSTIC-FACTOROXALIPLATINFLUOROURACIL
相关
加载中…
  • Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study
    Meng, Qianhao; Zhao, Jian; Yu, Yuanyuan; Wang, Ke; Ren, Jing; Xu, Chang; Wang, Yusheng*; Wang, Guangyu*BMC CANCER, 2023, 23(1): 191.被引 1
  • CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.
    Xu, Jianming; Cao, Bangwei; Gu, Kangsheng; Bai, Yuxian; Li, Wei; Zhang, Jingdong; Liu, Caigang; Niu, Zuoxing; Zhang, Liangming; Zhong, Haijun; Luo, Suxia; Zhou, Jian-Wei; Liu, Tianshu; Gu, Yanhong; Lin, Jingguan; Deng, Yanhong; Chen, Chuangqi; Li, Yunfeng; Yang, Xiuli; Li, BihuiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
  • A multicenter, randomized, open-label, phase III study of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer
    Ding, K.; Liu, Y.; Song, Y.; Xu, D.; Li, J.; Wang, J.; Chen, X.; Lin, R.; Jiang, Y.; Zhang, Y.; Zhang, W.; Cheng, Y.; Wu, X.; Yuan, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
查看全部 →

发表信息

论文状态
公开发表
期刊
Scientific Reports
发表日期
2020-07-23
卷期
第 10 卷, 第 1 期
页码
12336
DOI
10.1038/s41598-020-69230-5
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
3区
成果收录
SCIE
资助标注
Natural Science Foundation of Guangdong Province [2017A030310337]; National Natural Science Foundation of China [81572409]; General Guidance Project of Health Science and Technology of Guangzhou [20191A011010]; Guangdong Medical Science and Technology Research Fund [C2018063]

作者

  • L

    Liu, Shousheng (第一作者)

    sun yat sen univ

  • J

    Jiang, Chang

    sun yat sen univ

查看全部 11 位作者收起作者
  • Y

    Yang, Lin

    southern med univ

  • H

    Huang, Jinsheng

    sun yat sen univ

  • P

    Peng, Roujun

    sun yat sen univ

  • W

    Wang, Xiaopai

    1 · 2 · guangzhou med univ

  • H

    He, Wenzhuo

    sun yat sen univ

  • B

    Bai, Long

    sun yat sen univ

  • Z

    Zhou, Yixin

    sun yat sen univ

  • Z

    Zhang, Bei (通讯)

    sun yat sen univ

  • X

    Xia, Liangping (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417